Organon Acquired by Sun Pharmaceutical Industries | Healthcare M&A Deal

Sun Pharmaceutical Industries has acquired Organon, a pharmacy business in New Jersey, for $11.75 billion enterprise valuation. Sun Pharmaceutical Industries acquisitions add Organon’s women’s health and general medicines portfolio, including biosimilars, commercialized across more than 140 countries, with major markets in the U.S., Europe, China, Canada, and Brazil. Organon acquisition strengthens healthcare M&A capabilities through established brands and regulatory trust, supporting Sun’s strategic acquisition of complementary product lines and global scale. The merger acquisition is an all-cash strategic acquisition announced in 2026, with Organon stockholders receiving $14.00 per share, and is structured as a merger acquisition with expected closing subject to customary approvals.